Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.3500 +0.0600 (+4.65%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.3500 unch (unch) 16:02 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2500
Day High
1.4200
Open 1.2600
Previous Close 1.2900 1.2900
Volume 192,200 192,200
Avg Vol 288,215 288,215
Stochastic %K 30.45% 30.45%
Weighted Alpha -29.88 -29.88
5-Day Change +0.0300 (+2.27%) +0.0300 (+2.27%)
52-Week Range 0.7260 - 4.2684 0.7260 - 4.2684
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,293
  • Shares Outstanding, K 63,180
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,050 K
  • EBIT $ -42 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 189.88% ( -56.21%)
  • Historical Volatility 94.58%
  • IV Percentile 65%
  • IV Rank 19.04%
  • IV High 775.99% on 07/01/24
  • IV Low 52.03% on 09/03/24
  • Put/Call Vol Ratio 12.14
  • Today's Volume 3,403
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 2.33
  • Today's Open Interest 34,842
  • Open Int (30-Day) 33,779

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +20.54%
on 04/04/25
Period Open: 1.6000
1.8207 -25.85%
on 03/26/25
-0.2500 (-15.63%)
since 03/11/25
3-Month
1.0700 +26.17%
on 01/14/25
Period Open: 1.1000
1.8207 -25.85%
on 03/26/25
+0.2500 (+22.73%)
since 01/10/25
52-Week
0.7260 +85.95%
on 12/20/24
Period Open: 4.2000
4.2684 -68.37%
on 04/12/24
-2.8500 (-67.86%)
since 04/11/24

Most Recent Stories

More News
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

GALT : 1.3500 (+4.65%)
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

GALT : 1.3500 (+4.65%)
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

GALT : 1.3500 (+4.65%)
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

GALT : 1.3500 (+4.65%)
TNXP : 16.88 (-2.43%)
CDIO : 0.4050 (+17.32%)
CADL : 4.97 (+4.19%)
RXRX : 5.76 (+27.72%)
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

GALT : 1.3500 (+4.65%)
Galectin Therapeutics Presents Clinical Data on NAVIGATE Trial for Esophageal Varices in MASH Cirrhosis at AASLD 2024

Galectin Therapeutics presents NAVIGATE trial findings on portal hypertension in MASH cirrhosis at AASLD 2024. Results expected December 2024.Quiver AI SummaryGalectin Therapeutics, Inc. has announced...

GALT : 1.3500 (+4.65%)
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

GALT : 1.3500 (+4.65%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

GALT : 1.3500 (+4.65%)
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

GALT : 1.3500 (+4.65%)
Rating the Top 4 Unusually Active Call Options From Thursday’s Trading

The top four unusually active call options in Thursday trading had an average Vol/OI ratio of 52.25. While that’s not very high, each has compelling reasons to buy. Here's why.

JPM : 236.20 (+4.00%)
FTDR : 39.92 (+0.81%)
GALT : 1.3500 (+4.65%)
KKR : 101.44 (-0.42%)
CPRI : 14.65 (+0.14%)
TPR : 63.40 (-0.81%)

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

3rd Resistance Point 1.6000
2nd Resistance Point 1.5100
1st Resistance Point 1.4300
Last Price 1.3500
1st Support Level 1.2600
2nd Support Level 1.1700
3rd Support Level 1.0900

See More

52-Week High 4.2684
Fibonacci 61.8% 2.9152
Fibonacci 50% 2.4972
Fibonacci 38.2% 2.0792
Last Price 1.3500
52-Week Low 0.7260

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar